Date: Tuesday 20 Mar 2012
Concerns about Anglo-Swedish drugs giant AstraZeneca's pipeline are likely to increase as the company abandoned work on its anti-depressant treatment TC-5214, which it developed in conjunction with US peer Targacept.
| AstraZeneca licences Targacept drug | 03-Dec-2009 | ShareCast |
| AstraZeneca buys into experimental antidepressan... | 04-Dec-2009 | Times |
| AstraZeneca strikes deal with Targacept over new... | 04-Dec-2009 | Guardian |
No recent information was found.
No recent information was found.
| Currency | US Dollars |
| Share Price | $ 4.15 |
| Change Today | $ -0.05 |
| % Change | -1.19 % |
| 52 Week High | $22.50 |
| 52 Week Low | $4.10 |
| Volume | 142,351 |
| Shares Issued | 33.40m |
| Market Cap | $138.61m |
| Beta | 0.62 |
| RiskGrade | 359 |
| Strong Buy | 1 |
| Buy | 0 |
| Neutral | 6 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 7 |

| Time | Volume / Share Price |
| 16:00 | 6,642 @ $4.15 |
| 15:59 | 200 @ $4.17 |
| 15:59 | 179 @ $4.16 |
| 15:59 | 100 @ $4.16 |
| 15:59 | 200 @ $4.16 |
You are here: research